VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
Company on track to initiate the TRILOGY Phase 3 program in 2021
Email Print Friendly Share
December 17, 2020 08:00 ET | Source: VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). The Company, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for FCD105 (3% minocycline / 0.3% adapalene foam), the first ever minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.
The End-of-Phase 2 meeting was supported by non-clinical safety, CMC and clinical information, including results from the previously completed positive Phase 2 study evaluating FCD105 in patients with moderate-to-severe acne vulgaris. In the Phase 2 study, FCD105 demonstrated potentially class-leading efficacy on the co-primary outcome measures of (1) Investigator’s Global Assessment (IGA) treatment success (IGA score “0” or “1” and at least a two-grade improvement from baseline) and (2) absolute change from baseline in mean inflammatory counts at Week 12.
The most commonly reported treatment-emergent adverse event in the trial was upper respiratory tract infection (4.9% in the vehicle treatment group) with dry skin being the most commonly reported cutaneous adverse event (3.6% in the 0.3% adapalene treatment group). The majority of adverse events were assessed as mild in severity. There were no serious adverse events. .
The meeting provided VYNE with clear direction on the Phase 3 clinical and pharmaceutical development plans for FCD105 and, should the clinical studies meet their objectives, the meeting provided further clarity on preparations required for the anticipated NDA. Specifically, key outcomes from the meeting included:
Agreement with FDA to conduct two, identical,12-week, double-blind Phase 3 efficacy and safety studies (TRILOGY-1 and TRILOGY-2). Each study will enroll 550 subjects aged 9 years and older with a clinical diagnosis of moderate-to-severe acne vulgaris. Subjects will be randomized 2:1 to received either FCD105 or vehicle respectively.
Agreement to conduct one, 40-week open-label Phase 3 safety study (TRILOGY-3) which will enroll a minimum of 450 subjects from the preceding 12-week double-blind studies. FDA agreed to accept the corresponding data from this study after the NDA has been submitted. It is expected that this will enable the NDA to be submitted earlier than originally planned.
The Phase 1 dermal safety program was reduced from the customary five studies to two studies comprising a Phase 1 safety/pharmacokinetic “bridging” study under maximum use treatment conditions and a photoallergenicity study. The latter study may not be required, pended further characterization of the product.
FDA agreed to a much-reduced pharmaceutical development and stability program which is expected to have positive impacts on both overall development cost and commercial product cost of goods, should FCD105 be approved.
“We are pleased with the outcome of our recent End-of-Phase 2 meeting with FDA and the collaborative and productive guidance we received for our program,” said David Domzalski, CEO of VYNE. “Alignment with the FDA on our Phase 3 clinical development plan provides clarity about our development pathway for FCD105 in acne and we look forward to commencing the program next year”.
About Acne
Acne is a chronic, inflammatory skin condition that affects the skin’s sebaceous glands and hair follicles. It is characterized by both inflammatory lesions (papules and pustules) and non-inflammatory lesions (open and closed comedones) affecting primarily the face and truncal areas of the body. Acne affects approximately 40 to 50 million people in the U.S. alone, of whom approximately 10 million have moderate to severe disease that may impact self-esteem and quality of life. For most people, acne diminishes over time and tends to disappear or decrease, by age 25. However, some individuals, particularly women, can experience acne much later in life.
About VYNE Therapeutics Inc.
VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI™ (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at amzeeq.com and ZILXI’s Full Prescribing Information at zilxi.com.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www. vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
